Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci’s scientific leadership in biologic drug creation.

 Absci Corporation, a generative AI drug creation company, announced the expansion of its Scientific Advisory Board with three world-class scientific leaders: Victor Greiff, Ph.D., Timothy Lu, MD, Ph.D., and Hubert Truebel, MD, Ph.D., MBA. These renowned leaders in AI drug design, synthetic biology, and translational medicine, respectively, will play a pivotal role in helping Absci continue to pioneer AI drug creation in its mission to create better biologics for patients, faster.

Recent AiThority News : Taboola Beta Tests Integration of Generative AI, Including ChatGPT, to Revolutionize Ad Creation for Advertisers

“We’re proud that our work in AI drug creation has attracted some of the most respected leaders in their fields to join us,” said Dr. Andreas Busch, Chief Innovation Officer at Absci. “It will take the best team in the industry to create life-changing medicines at unprecedented speed, and these three new SAB members reflect Absci’s leading approach to integrating AI and wet biology to create development assets. Dr. Greiff’s expertise in developing machine learning models for in silico antibody design, Dr. Lu’s expertise in biological engineering, and Dr. Truebel’s work in translational medicine give us invaluable expertise that will strengthen Absci’s leadership in in silico drug creation.”

Dr. Victor Greiff is an Associate Professor of Systems Immunology at the University of Oslo. Dr. Greiff’s group develops machine learning and experimental tools for analyzing antibody and T-cell repertoires to facilitate the in silico design of immune receptor-based immunodiagnostics and immunotherapeutics. Dr. Greiff earned his Ph.D. from Humboldt-University Berlin, Germany, and conducted his postdoctoral research in the laboratory of Sai T. Reddy at ETH Zürich, Switzerland. A recognized expert in the in silico design of immune receptor-based therapies and diagnostics, Dr. Greiff currently serves as the Executive Sub-committee Chair of the Adaptive Immune Receptor Repertoire Community of The Antibody Society.

“Absci’s ability to create and validate antibodies from scratch with AI highlights the breakthrough research occurring at Absci,” said Dr. Greiff. “In silico drug design requires vast amounts of high-quality wet lab datasets to effectively build and train generative AI models. The biological data that Absci has accumulated and continues to produce at an incredible scale gives them a major advantage in creating medicines of the future, and together I am confident we can advance breakthrough new medicines for patients in need.”

NLP News: Fast Track Unleashes the Power of AI-Language Technology for Automated Campaign Generation

Dr. Timothy Lu is a biotech entrepreneur and Associate Professor of Biological Engineering and Electrical Engineering and Computer Science at the Massachusetts Institute of Technology (MIT). Dr. Lu has served as a co-founder and Scientific Advisory Board member to many biotechnology and biopharmaceutical companies. Dr. Lu earned his M.D. from Harvard Medical School and his Ph.D. jointly from MIT and Harvard University. Dr. Lu is a core member of the Synthetic Biology Center at MIT and an Associate Member at the Broad Institute of MIT and Harvard.

“Absci is harnessing generative AI to pioneer the next frontier of antibody drug discovery to deliver better drugs to patients faster,” said Dr. Lu. “The company has already demonstrated unique capabilities in integrating its wet lab capabilities with AI to rapidly create biologics that are more likely to have higher clinical success rates. I look forward to helping them progress their pipeline and bring new drugs to the clinic at incredible speeds.”

Dr. Hubert Truebel is the Chief Medical Officer & Head of Clinical Development at AiCuris. With his 20+ years of academic and industry experience, Dr. Truebel brings an extensive track record of progressing a wide variety of innovative therapeutics through clinical development, agency approval, and ultimately to patients. Dr. Truebel has held numerous leadership roles at leading pharmaceutical companies, most recently as SVP & Head of Translational Medicine for Bayer Pharma R&D. He received his M.D. from Johannes Gutenberg University, his postdoctoral training at Yale University Medical School, and his MBA from the University of Illinois Urbana-Champaign.

“Absci’s ability to identify novel drug targets, create and optimize high-potential biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process is truly unique in drug creation,” said Dr. Truebel. “Absci’s approach can potentially reduce preclinical development timelines and increase the probability of success in the clinic. Joining Absci’s Scientific Advisory Board alongside Dr. Greiff and Dr. Lu will bring us one step closer to the vision of breakthrough therapeutics at the click of a button.”

 Latest Aithority Insights : Squashing Long Wait Time & Call Friction: AI’s Role in Transforming Contact Centers

 [To share your insights with us, please write to sghosh@martechseries.com]